TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.
Saved in:
| Title: | TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. |
|---|---|
| Authors: | Wu B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA lellisen@mgh.harvard.edu wu.bogang@mayo.edu.; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Thant W; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Bitman E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Liu T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Liu J; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA.; Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA., Paschalis EI; Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA., Patel BK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Nawrocki C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Xu KH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Nieman LT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Ting DT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., de Gois Macedo B; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Cheng Y; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Jiang K; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Sun F; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Thimmiah N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Sun S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Abelman RO; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Bossuyt VI; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Isakoff SJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Ellisen LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA lellisen@mgh.harvard.edu wu.bogang@mayo.edu.; Ludwig Center at Harvard, Boston, Massachusetts, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Apr 03; Vol. 14 (4). Date of Electronic Publication: 2026 Apr 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
